Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07033494 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
A Phase 2 study of Early Alzheimer's Disease, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 340
- Enrollment target
- 20
- Study locations
NCT07033494 is a Phase 2 study of Early Alzheimer's Disease that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 340 participants, below the 1,053-participant average among 7 other Early Alzheimer's Disease trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT07033494, a Phase 2 study of Early Alzheimer's Disease, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 340 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL MK-2214
Study Locations (20)
Florida
- JEM Research Institute ( Site 1046) - Atlantis
- Neuropsychiatric Research Center of Southwest Florida ( Site 1003) - Fort Myers
- Indago Research & Health Center, Inc ( Site 1044) - Hialeah
- K2 Medical Research ( Site 1047) - Maitland
- ClinCloud LLC ( Site 1039) - Melbourne
- Aqualane Clinical Research ( Site 1035) - Naples
- Suncoast Clinical Research ( Site 1007) - New Port Richey
- Renstar Medical Research ( Site 1012) - Ocala
- Charter Research - Orlando ( Site 1051) - Orlando
- Axiom Brain Health ( Site 1029) - Tampa
- K2 Medical Research ( Site 1020) - Tampa
- Charter Research - Lady Lake ( Site 1019) - The Villages
- Conquest Research LLC ( Site 1053) - Winter Park
California
- Inglewood Clinical ( Site 1062) - Inglewood
- Irvine Clinical Research ( Site 1041) - Irvine
- Healthy Brain Clinic ( Site 1005) - Long Beach
- Anderson Clinical Research ( Site 1024) - Redlands
- UCSF Memory and Aging Center ( Site 1031) - San Francisco
- Syrentis Clinical Research ( Site 1001) - Santa Ana
Connecticut
- Yale University, Alzheimer's Disease Research Unit ( Site 1059) - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2029-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07033494
The ClinicalTrials.gov registry entry for NCT07033494 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,053-participant average among 7 other Early Alzheimer's Disease trials with a reported enrollment target (68% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Alzheimer's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07033494 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07033494 about?
NCT07033494 is a clinical study titled "A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)". Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to d...
What is the current status of trial NCT07033494?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2025-07-16. Estimated completion is 2029-04-30.
What conditions does trial NCT07033494 study?
This clinical trial studies the following conditions: Early Alzheimer's Disease.
What interventions are being tested in trial NCT07033494?
The interventions under investigation include: Placebo (DRUG), MK-2214 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07033494?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07033494 being conducted?
This trial has 20 study locations across California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
RECRUITING · Phase 3
-
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.